Fanconi anemia is a rare and severe inherited genetic disorder characterized by progressive bone marrow failure, physical malformations, and a heightened cancer predisposition, with affected individuals facing a life expectancy of approximately 30 years.
Return of a Spanish-Developed Gene Therapy
The treatment approach stems from research originally conducted in Spain. The project was initially licensed to Rocket Pharma, a U.S. pharmaceutical company that advanced the therapeutic candidate through international clinical trials. However, shifting corporate strategies and changes among investors prompted the company to withdraw from the program. This corporate realignment returned the development of the treatment to Spain.
Timeline for First Patient Administration
Bueren, director of the Biomedical Innovation Unit at the Centre for Energy, Environmental and Technological Research (CIEMAT) and an international authority in gene and cell therapy, announced the milestone during the Biospain biotechnology congress held in Barakaldo, Bizkaia. He stated that researchers aim to complete this process within a maximum timeframe of a year and a half. If approvals are secured on schedule, the Hospital Universitario Infantil Niño Jesús will administer the therapy to its first patient under this pathway.
Advancements in Leukocyte Adhesion Deficiency Treatment
During his presentation at Biospain, Bueren also detailed progress on KRESLADI, another advanced gene therapy originating from Spanish research. KRESLADI targets leukocyte adhesion deficiency-1 (LAD-1), a rare genetic immunodeficiency that prevents white blood cells from migrating toward sites of infection. Because LAD-1 carries a high mortality rate during early childhood, both this immunodeficiency treatment and the Fanconi anemia program highlight the translation of Spanish biomedical research into international clinical applications.
Clinical Outlook and Next Steps
- Target Timeline: Clinical administration at the Madrid hospital is projected for approximately a year and a half, pending regulatory authorization.
- Institutional Involvement: CIEMAT and the Hospital Universitario Infantil Niño Jesús are involved in the return of the treatment to the Spanish healthcare system.
- Broad Pipeline: The return of the Fanconi anemia program coincides with progress for KRESLADI in treating severe pediatric immunodeficiencies.
Related reading